Status:
UNKNOWN
A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIP Study)
Lead Sponsor:
Tongji Hospital
Conditions:
End Stage Liver Disease
Infection
Eligibility:
All Genders
Brief Summary
Spontaneous bacterial peritonitis (SBP) is a common complication of end-stage liver disease due to various causes. The initial anti-infective medication is appropriate and the patient's survival rate ...
Eligibility Criteria
Inclusion
- Meet the end-stage liver disease part of the type of standard (including slow plus acute liver failure, chronic liver failure, cirrhosis decompensation);
- age\> 18 years old
- ascites nucleated cell count\> 250 × 106 / L;
- Unable to obtain ascites specimens or ascites nucleated cells count does not meet the conditions of 3) are required abdominal examination tenderness (+), rebound tenderness (+), abdominal ultrasound can detect ascites, and procalcitonin (PCT) \> 0.5ng / ml, hs-CRP\> 10ng / ml
Exclusion
- history of abdominal surgery within 4 weeks;
- secondary peritonitis;
- tuberculous peritonitis;
- Malignant tumor;
- patients who use hormones or immunosuppressants;
- AIDS patients;
- heart failure or respiratory failure;
- merge other parts of the infection;
- died within 48h;
- liver transplantation during observation;
- Diagnosis of spontaneous bacterial peritonitis is the use of carbapenems or third-generation cephalosporins / enzyme inhibitors, piperacillin / enzyme inhibitor antibiotics
Key Trial Info
Start Date :
July 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2019
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03362632
Start Date
July 1 2018
End Date
June 30 2019
Last Update
September 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030